1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Type 2 Diabetes Management Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Type 2 Diabetes Management Market, by Drug Class
8.1.1. Oral Medications
8.1.1.1. Market Revenue and Forecast
8.1.2. Injectable Medications
8.1.2.1. Market Revenue and Forecast
9.1. Type 2 Diabetes Management Market, by Device Type
9.1.1. Monitoring Devices-
9.1.1.1. Market Revenue and Forecast
9.1.2. Prefilled Pens
9.1.2.1. Market Revenue and Forecast
9.1.3. Reusable Pens
9.1.3.1. Market Revenue and Forecast
10.1. Type 2 Diabetes Management Market, by End-User
10.1.1. Healthcare Providers
10.1.1.1. Market Revenue and Forecast
10.1.2. Patients
10.1.2.1. Market Revenue and Forecast
10.1.3. Caregivers
10.1.3.1. Market Revenue and Forecast
11.1. Type 2 Diabetes Management Market, by Distribution Channel
11.1.1. Pharmacies
11.1.1.1. Market Revenue and Forecast
11.1.2. Hospitals and Clinics
11.1.2.1. Market Revenue and Forecast
11.1.3. Direct-to-Consumer
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Drug Class
12.1.2. Market Revenue and Forecast, by Device Type
12.1.3. Market Revenue and Forecast, by End-User
12.1.4. Market Revenue and Forecast, by Distribution Channel
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Drug Class
12.1.5.2. Market Revenue and Forecast, by Device Type
12.1.5.3. Market Revenue and Forecast, by End-User
12.1.5.4. Market Revenue and Forecast, by Distribution Channel
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Drug Class
12.1.6.2. Market Revenue and Forecast, by Device Type
12.1.6.3. Market Revenue and Forecast, by End-User
12.1.6.4. Market Revenue and Forecast, by Distribution Channel
12.2. Europe
12.2.1. Market Revenue and Forecast, by Drug Class
12.2.2. Market Revenue and Forecast, by Device Type
12.2.3. Market Revenue and Forecast, by End-User
12.2.4. Market Revenue and Forecast, by Distribution Channel
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Drug Class
12.2.5.2. Market Revenue and Forecast, by Device Type
12.2.5.3. Market Revenue and Forecast, by End-User
12.2.5.4. Market Revenue and Forecast, by Distribution Channel
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Drug Class
12.2.6.2. Market Revenue and Forecast, by Device Type
12.2.6.3. Market Revenue and Forecast, by End-User
12.2.6.4. Market Revenue and Forecast, by Distribution Channel
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Drug Class
12.2.7.2. Market Revenue and Forecast, by Device Type
12.2.7.3. Market Revenue and Forecast, by End-User
12.2.7.4. Market Revenue and Forecast, by Distribution Channel
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Drug Class
12.2.8.2. Market Revenue and Forecast, by Device Type
12.2.8.3. Market Revenue and Forecast, by End-User
12.2.8.4. Market Revenue and Forecast, by Distribution Channel
12.3. APAC
12.3.1. Market Revenue and Forecast, by Drug Class
12.3.2. Market Revenue and Forecast, by Device Type
12.3.3. Market Revenue and Forecast, by End-User
12.3.4. Market Revenue and Forecast, by Distribution Channel
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Drug Class
12.3.5.2. Market Revenue and Forecast, by Device Type
12.3.5.3. Market Revenue and Forecast, by End-User
12.3.5.4. Market Revenue and Forecast, by Distribution Channel
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Drug Class
12.3.6.2. Market Revenue and Forecast, by Device Type
12.3.6.3. Market Revenue and Forecast, by End-User
12.3.6.4. Market Revenue and Forecast, by Distribution Channel
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Drug Class
12.3.7.2. Market Revenue and Forecast, by Device Type
12.3.7.3. Market Revenue and Forecast, by End-User
12.3.7.4. Market Revenue and Forecast, by Distribution Channel
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Drug Class
12.3.8.2. Market Revenue and Forecast, by Device Type
12.3.8.3. Market Revenue and Forecast, by End-User
12.3.8.4. Market Revenue and Forecast, by Distribution Channel
12.4. MEA
12.4.1. Market Revenue and Forecast, by Drug Class
12.4.2. Market Revenue and Forecast, by Device Type
12.4.3. Market Revenue and Forecast, by End-User
12.4.4. Market Revenue and Forecast, by Distribution Channel
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Drug Class
12.4.5.2. Market Revenue and Forecast, by Device Type
12.4.5.3. Market Revenue and Forecast, by End-User
12.4.5.4. Market Revenue and Forecast, by Distribution Channel
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Drug Class
12.4.6.2. Market Revenue and Forecast, by Device Type
12.4.6.3. Market Revenue and Forecast, by End-User
12.4.6.4. Market Revenue and Forecast, by Distribution Channel
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Drug Class
12.4.7.2. Market Revenue and Forecast, by Device Type
12.4.7.3. Market Revenue and Forecast, by End-User
12.4.7.4. Market Revenue and Forecast, by Distribution Channel
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Drug Class
12.4.8.2. Market Revenue and Forecast, by Device Type
12.4.8.3. Market Revenue and Forecast, by End-User
12.4.8.4. Market Revenue and Forecast, by Distribution Channel
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Drug Class
12.5.2. Market Revenue and Forecast, by Device Type
12.5.3. Market Revenue and Forecast, by End-User
12.5.4. Market Revenue and Forecast, by Distribution Channel
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Drug Class
12.5.5.2. Market Revenue and Forecast, by Device Type
12.5.5.3. Market Revenue and Forecast, by End-User
12.5.5.4. Market Revenue and Forecast, by Distribution Channel
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Drug Class
12.5.6.2. Market Revenue and Forecast, by Device Type
12.5.6.3. Market Revenue and Forecast, by End-User
12.5.6.4. Market Revenue and Forecast, by Distribution Channel
13.1. Boehringer Ingelheim International GmbH:
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bayer AG
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Dexcom, Inc
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Medtronic PLC:
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Merck & Co., Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Abbott Laboratories
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. AstraZeneca PLC
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Abbott
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Eli Lilly and Co.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Novo Nordisk
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
